More specifically, exon skipping therapies designed for the treatment of DMD are capable of providing expression of truncated dystrophin protein in skeletal muscle and, in return, may delay the progression of the disease [9, 10]. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.